Products

MODURETIC is indicated in the treatment of patients with

• - oedema of cardiac origin;
• - hepatic cirrhosis with ascites;
• - hypertension in whom potassium depletion might be anticipated.

MODURETIC, with its combination of amiloride HCl and hydrochlorothiazide, minimises the possibility of the development of excessive potassium loss in patients during vigorous diuresis for prolonged periods. MODURETIC, with its built-in potassium sparing agent, is especially indicated in those conditions where the positive effect on potassium balance is particularly important.

MODURETIC may be used alone, or as an adjunct to other antihypertensive drugs. Since it enhances the action of these agents, the dosage of these antihypertensive drugs may need to be reduced to avoid the risk of an excessive drop in blood pressure.

Oral Administration: MYAMBUTOL is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. It has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculous meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculosis of the skin and tuberculous eye diseases. It should not be used as the sole antituberculosis drug, but should be used in conjunction with at least one other antituberculosis drug. Selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies. In patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs - MYAMBUTOL, isoniazid, rifampicin and streptomycin - for the first 2-4 months: for example, MYAMBUTOL plus isoniazid plus rifampicin or MYAMBUTOL plus isoniazid plus streptomycin then continuing with a two drug regimen such as MYAMBUTOL plus isoniazid or MYAMBUTOL plus rifampicin. In patients who have received previous antituberculosis therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. Consequently, in such retreatment cases MYAMBUTOL should be combined with at least one of the second-line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. Antituberculosis drugs used with MYAMBUTOL have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. Isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. Alternating drug regimens have also been utilised.

Treatment of cutaneous mycotic infections caused by Candida sp.

Treatment of chronic granulocytic leukaemia. It has been shown to be superior to splenic irradiation when judged by survival times, control of spleen size and maintenance of haemoglobin levels. Although not curative, busulfan reduces the total granulocyte mass, relieves disease symptoms and improves the clinical state of the patient. Busulfan is not useful once blast transformation has occurred.

Busulfan produces prolonged remission in polycythaemia vera. It is especially useful in cases 32 resistant to radiophosphorus ( P) and where there is marked thrombocytosis. Busulfan is useful in selected cases of essential thrombocythaemia and myelofibrosis.

For the treatment of intestinal infections caused by Candida albicans and other candida species.

Infections of the oral cavity caused by Candida albicans.

The cream is indicated in the local treatment of vulvovaginal candidiasis.

For relief from pain and fever for children and babies.

To reduce the frequency of moderate to severe attacks of angina pectoris due to coronary artery disease in patients who have not responded to other conventional therapy or in whom such therapy may be contra-indicated. Note: Because of the serious nature of potential side effects, perhexiline maleate should be reserved for use in patients with intractable angina who are refractory or intolerant to other agents and are not suitable candidates for coronary bypass surgery.

Treatment of acute leukaemia. It is of value in remission induction and is particularly indicated for maintenance therapy in acute lymphoblastic leukaemia and acute myelogenous leukaemia. PURI-NETHOL is also used in the treatment of chronic granulocytic leukaemia.

Wherever corticosteroid therapy is indicated.

1. As a preoperative antimuscarinic to reduce salivary, tracheobronchial and pharyngeal secretions, and to reduce the acidity and volume of the gastric contents. 2. As a preoperative or intra-operative antimuscarinic to attenuate or prevent intra- operative bradycardia associated with the use of suxamethonium or due to cardiac vagal reflexes. 3. To protect against the peripheral muscarinic actions (e.g. bradycardia and excessive secretions) of anticholinesterases such as neostigmine or pyridostigmine given to reverse neuromuscular blockade produced by non-depolarising muscle relaxants.

Chronic Therapy: The management of manifestations of psychotic disorders such as schizophrenia, psychosis due to organic brain damage or mental deficiency, senile psychosis, the manic phase of manic depressive illness, Gilles de la Tourette syndrome. Short Term Therapy:The treatment of acute alcoholism for the relief of delusions, hallucinations and confused states, and for the control of accompanying tremulousness and aggressive behaviour. In the treatment of intractable nausea and vomiting associated with radiation or malignancy and not responding to other therapy. Neuroleptanalgesia.

Chronic Therapy: The management of manifestations of psychotic disorders such as schizophrenia, psychosis due to organic brain damage or mental deficiency, senile psychosis, the manic phase of manic depressive illness, Gilles de la Tourette syndrome. Short Term Therapy:The treatment of acute alcoholism for the relief of delusions, hallucinations and confused states, and for the control of accompanying tremulousness and aggressive behaviour. In the treatment of intractable nausea and vomiting associated with radiation or malignancy and not responding to other therapy. Neuroleptanalgesia.

Renal failure associated with renal tubular acidosis in which bicarbonate replacement becomes necessary.

Treatment of all types of potassium deficiencies, particularly hypochloraemic or hypokalaemic alkalosis, associated with prolonged or intensive diuretic therapy, e.g. in hypertension, cardiac failure or massive oedema (potassium replacement is particularly important to patients receiving digitalis, as the clinical response to this drug is seriously affected by hypokalaemia), in renal disease associated with increased potassium excretion, e.g. nephrotic syndrome; vomiting and diarrhoea, ulcerative colitis, steatorrhoea, diabetes insipidus, and uncontrolled diabetes mellitus; ileostomy or colostomy patients, cirrhosis; Cushing's syndrome and dietary insufficiency; during prolonged or intensive treatment with corticosteroids, ACTH or carbenoxolone; hyperaldosteronism in megaloblastic anaemia, during the early stages of treatment. Here Span-K is indicated if a diet rich in potassium cannot be guaranteed.